Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression

Cancer

Volumn 86, Issue 4, 1999, Pages 672-683

  Perry, Arie ^a   Jenkins, Robert B ^b   O'Fallon, Judith R ^b   Schaefer, Paul L ^c   Kimmel, David W ^b   Mahoney, Michelle R ^b   Scheithauer, Bernd W ^b   Smith, Sandra M ^b   Hill, Eunice M ^b   Sebo, Thomas J ^b   Levitt, Ralph ^d   Krook, James ^e   Tschetter, Loren K ^f   Morton, Roscoe F ^g   Buckner, Jan C ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c Toledo Community Hospital Oncology Program   (United States)

^d MeritCare Hospital   (United States)

^e Duluth CCOP   (United States)

^f Sioux Community Cancer Consortium   (United States)

^g Iowa Oncology Research Association CCOP   (United States)

Author keywords

Astrocytoma; Flow cytometry; Glioma; Immunohistochemistry; Ki 67; p53 protein; Prognosis; Proliferating cell nuclear antigen; Proliferation

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CELL DIVISION; COHORT STUDIES; DNA, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033567041     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990815)86:4<672::AID-CNCR17>3.0.CO;2-G     Document Type: Article

References (57)

1. Schuurman PR, Troost D, Verbeeten B Jr., Bosch DA. Five-year survival and clinical prognostic factors in progressive supratentorial diffuse "low-grade" astrocytoma: a retrospective analysis of 46 cases. Acta Neurochirurg 1997;139:2-7.
2. Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A. Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol 1995;44:208-21.
3. Loiseau H, Bousquet P, Rivel J, Vital C, Kantor G, Rougier A, et al. Astrocytomes de bas grade sus-tentoriels de l'adulte. Facteurs pronostics et indications therapeutiques. A propos d'une serie de 141 patients. Neuro-Chirurgie 1995;41:38-50.
4. Fischbach AJ, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J, et al. Long-term survival in treated anaplastic astrocytomas. A report of combined RTOG/ECOG studies. Am J Clin Oncol 1991;14:365-70.
5. Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997;80:242-9.
6. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 1997;911-4.
7. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. World Health Organization. New York: Springer-Verlag, 1993.
8. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62:2152-65.
9. Zubrod CG, Schneiderman M, Frei E III, Brindley C, Gold GL, Shnider B, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960;7-33.
10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55.
11. Elliott TE, Dinapoli RP, O'Fallon JR, Krook JE, Earle JE, Morton RF, et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high-grade astrocytoma. J Neuro Oncol 1997;33:239-50.
12. Dinapoli RP, Brown LD, Arusell RM, Earle JD, O'Fallon JR, Buckner JC, et al. Phase III comparative evaluation of PCNU and BCNU combined with radiation therapy for high-grade glioma. J Clin Oncol 1993;11:1316-21.
13. Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O'Fallon JR. Phase III study of radiation therapy (RT) plus BCNU with or without recombinant Interferon alpha (IFN) in high grade glioma: an NCCTG study. Proc Am Soc Clin Oncol 1997;16:385a(A1374).
14. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997;86:121-30.
15. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, et al. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 1994;74:920-7.
16. Dressler LG, Seemer L, Owens MA, Clark GM, McGuire WL. Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Res 1987;47:5294-302.
17. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992;11:2093-109.
18. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979;7:1-26.
19. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas: an MIB-1 labeling index study. J Neuropathol Exp Neurol 1999;58:46-53.
20. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1 (Ki-67) immunoreactivity in differentiating Grade II and Grade III gliomas. J Neuropathol Exp Neurol 1997;56: 857-65.
21. Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT. Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 1997;34:31-5.
22. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997;56:798-805.
23. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatr 1995;59:413-9.
24. Winger MJ, MacDonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487-93.
25. Vecht CJ, Avezaat CJJ, van Putten WLJ, Eijkenboom WMH, Stefanko SZ. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatr 1990;53:466-71.
26. Phillips TL, Levin VA, Ahn DK, Gutin PH, Davis RL, Wilson CB, et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int J Radiat Oncol Biol Phys 1991;21:709-14.
27. Duncan GG, Goodman GB, Ludgate CM, Rheaume DE. The treatment of adult supratentorial high grade astrocytomas. J Neurooncol 1992;13:63-72.
28. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-44.
29. Halperin EC, Gaspar L, Imperato J, Salter M, Herndon J, Dowling S. An analysis of radiotherapy data from the CNS Cancer Consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. Am J Clin Oncol 1993;16:277-83.
30. Yaneva M, Arolski I, Iliev E, Zaprianov Z. Factors influencing prognosis of patients with CNS supratentorial astroglial tumors who underwent postoperative radiotherapy. Folia Medica 1993;35:49-54.
31. Sneed PK, Prados MD, McDermott MW, Larson DA, Malec MK, Lamborn KR, et al. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 1995;36:898-903.
32. Gundersen S, Lote K, Hannisdal E. Prognostic factors for glioblastoma multiforme. Development of a prognostic index. Acta Oncol 1996;35(Suppl 8):123-7.
33. Coons SW, Johnson PC, Pearl DK. Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human astrocytomas. Neurosurgery 1994;35:119-26.
34. Varuch L, Nordenskuold B, Carstensen J, Enestrom S. Prognostic value of flow cytometry and correlation to some conventional prognostic factors: a retrospective study of archival specimens of 134 astrocytomas. J Neurosurg 1996; 85:146-51.
35. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann G III, Erickson RK, Hekmatpanah J, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997;41:1028-36.
36. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3: 19-26.
37. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-24.
38. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yammamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996; 77:373-80.
39. Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y, Gutman F. Retreatment of intracranial gliomas. Southern Med J 1994; 87:211-4.
40. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15:1294-301.
41. Tamura M, Zama A, Kurihara H, Kano T, Imai H, Ishiuchi S, et al. Clinicohistological study of oligodendroglioma and oligoastrocytoma. Brain Tumor Pathol 1997;14:35-9.
42. Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997;31:273-8.
43. Coons SW, Pearl DK. Mitosis identification in diffuse gliomas. Implications for tumor grading. Cancer 1998;82: 1550-5.
44. Shapiro JR, Mehta BM, Ebrahim SAD, Scheck AC, Moots PL, Fiola MR. Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas. In: Sudilovsky O, Pilot HC, Liotta LA, editors. Boundaries between promotion and progression during carcinogenesis. New York: Plenum Publishing Corp., 1991:243-262.
45. Coons SW, Johnson PC, Shapiro JR. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. Cancer Res 1995;55:1569-77.
46. Cho KG, Nagashima T, Barnwell S, Hoshino T. Flow cytometric determination of modal DNA population in relation to proliferative potential of human intracranial neoplasms. J Neurosurg 1988;69:588-92.
47. Nishizaki T, Orita T, Furutani Y, Ikeyama Y, Aoki H, Sasaki K. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 labeling indices in human brain tumors. J Neurosurg 1989;70:379-84.
48. Danova M, Giaretti W, Merlo F, Mazzini G, Gaetani P, Geido E, et al. Prognostic significance of nuclear DNA content in human neuroepithelial tumors. Int J Cancer 1991;48:663-7.
49. Jiminez O, Timms A, Quirke P, McLaughlin JE. Prognosis on malignant glioma. A retrospective study of biopsy specimens by flow cytometry. Neuropathol Appl Neurobiol 1989; 15:331-8.
50. Mork SJ, Laerum OD. Modal DNA content of human intracranial neoplasms studied by flow cytometry. J Neurosurg 1980;53:198-204.
51. Kirkegaard LJ, DeRose PB, Yao B, Cohen C. Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas. Prognostic significance. Am J Clin Pathol 1998;109:69-74.
52. Ono Y, Tamiya T, Ichikawa T, Matsumoto K, Furuta T, Ohmoto T, et al. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol 1997;94:21-7.
53. Kordek R, Biernat W, Alwasiak J, Maculewicz R, Yanagiahara R, Libersi PP. p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neurooncol 1995;26:11-6.
54. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery 1995;37:246-54.
55. al-Sarraj S, Bridges LR. p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 1995;9: 143-9.
56. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-8.
57. Yaziji H, Massarani-Wafai R, Gujrati M, Kuhns JG, Martin AW, Parker JC Jr. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol 1996;20:1086-90.